Behavioural Risk for HIV, Hepatitis B, and Hepatitis C Infections among a Population of Drug Users and Injectors across Four Regions in Ghana.


Journal

Interdisciplinary perspectives on infectious diseases
ISSN: 1687-708X
Titre abrégé: Interdiscip Perspect Infect Dis
Pays: Egypt
ID NLM: 101496545

Informations de publication

Date de publication:
2022
Historique:
received: 25 06 2022
accepted: 13 08 2022
entrez: 12 9 2022
pubmed: 13 9 2022
medline: 13 9 2022
Statut: epublish

Résumé

Blood borne infections such as HIV, Hepatitis B (HBV), and Hepatitis C (HCV) are of great importance to governments and their implementing partners, especially among people who use drugs (PWUD) and people who inject drugs (PWID). Prevalence and determinants of HIV, HBV, and HCV among PWUD and PWID in Ghana are not well established, the significance of this study. This assessment was a cross-sectional study implemented via the respondent driven sampling approach. A team of community advisory boards that comprised former users, current users, and civil society organizations were constituted to help in the implementation of the study. The study was conducted in four regions in Ghana. The assessment was based on a representation of populations of PWID and PWUD from the four regions. Efforts were made by the team to ensure adequate representation of women where feasible. A quantitative questionnaire was developed and used to obtain information on the respondents' sociodemographics, sexual behavior, substance use, and biological characteristics. The prevalence of HIV, HBV, and HCV among PWID and PWUD was determined using blood samples. First response and oral quick test for confirmation of HIV positivity were carried out, while SD bioline was used to test for the presence of HBV and HBC. Data were analyzed using the Bayesian generalized linear model via the binomial family of distributions under the logit link function with weak Cauchy and Normal distribution as prior. A total of 323 PWUD and PWID participants were interviewed across four regions of Ghana. The overall median age of the respondents was 36 (28, 43) years. The prevalence of HIV, HBV, and HCV infection in the study was 2.5%, 4.6%, and 5.9%, respectively. The prevalence of HIV, HBV, and HCV among drug users was 2.5% (95% CI: 0.7%-4.2%), 4.1% (95% CI: 1.8%-6.2%), and 6.7% (95% CI: 3.9%-9.4%), respectively. Most drug injectors and users started using and injecting drugs at ages less than 20 years and between 20 and 29 years, respectively. Drug users who identified themselves as part of the general population were 66% less likely to be tested HIV positive (POR = 0.34, CrI: 0.12-0.81) compared to sex workers. Part time employment respondents had fivefold odds (POR = 5.50, CrI: 1.20-16.16) of being HBV positive as against full-time employment. Most of the injectors and users started drugs at an early age. Drug users and injectors are at higher risk of these infections because of associated risky sexual behaviors and risky injection practices. Harm reduction programs to help addicts who are willing to quit the practice are recommended.

Sections du résumé

Background UNASSIGNED
Blood borne infections such as HIV, Hepatitis B (HBV), and Hepatitis C (HCV) are of great importance to governments and their implementing partners, especially among people who use drugs (PWUD) and people who inject drugs (PWID). Prevalence and determinants of HIV, HBV, and HCV among PWUD and PWID in Ghana are not well established, the significance of this study.
Method UNASSIGNED
This assessment was a cross-sectional study implemented via the respondent driven sampling approach. A team of community advisory boards that comprised former users, current users, and civil society organizations were constituted to help in the implementation of the study. The study was conducted in four regions in Ghana. The assessment was based on a representation of populations of PWID and PWUD from the four regions. Efforts were made by the team to ensure adequate representation of women where feasible. A quantitative questionnaire was developed and used to obtain information on the respondents' sociodemographics, sexual behavior, substance use, and biological characteristics. The prevalence of HIV, HBV, and HCV among PWID and PWUD was determined using blood samples. First response and oral quick test for confirmation of HIV positivity were carried out, while SD bioline was used to test for the presence of HBV and HBC. Data were analyzed using the Bayesian generalized linear model via the binomial family of distributions under the logit link function with weak Cauchy and Normal distribution as prior.
Results UNASSIGNED
A total of 323 PWUD and PWID participants were interviewed across four regions of Ghana. The overall median age of the respondents was 36 (28, 43) years. The prevalence of HIV, HBV, and HCV infection in the study was 2.5%, 4.6%, and 5.9%, respectively. The prevalence of HIV, HBV, and HCV among drug users was 2.5% (95% CI: 0.7%-4.2%), 4.1% (95% CI: 1.8%-6.2%), and 6.7% (95% CI: 3.9%-9.4%), respectively. Most drug injectors and users started using and injecting drugs at ages less than 20 years and between 20 and 29 years, respectively. Drug users who identified themselves as part of the general population were 66% less likely to be tested HIV positive (POR = 0.34, CrI: 0.12-0.81) compared to sex workers. Part time employment respondents had fivefold odds (POR = 5.50, CrI: 1.20-16.16) of being HBV positive as against full-time employment.
Conclusion UNASSIGNED
Most of the injectors and users started drugs at an early age. Drug users and injectors are at higher risk of these infections because of associated risky sexual behaviors and risky injection practices. Harm reduction programs to help addicts who are willing to quit the practice are recommended.

Identifiants

pubmed: 36092389
doi: 10.1155/2022/2544481
pmc: PMC9458387
doi:

Types de publication

Journal Article

Langues

eng

Pagination

2544481

Informations de copyright

Copyright © 2022 Chris Guure et al.

Déclaration de conflit d'intérêts

The authors declare that they have no competing interests.

Références

J Abnorm Psychol. 1988 May;97(2):168-80
pubmed: 3290306
Health Educ Res. 2001 Aug;16(4):457-69
pubmed: 11525392
World J Gastroenterol. 2014 May 28;20(20):6252-61
pubmed: 24876746
Lancet. 2015 Jan 17;385(9964):287-301
pubmed: 25059950
Arch Public Health. 2018 Sep 17;76:51
pubmed: 30237881
Sociol Health Illn. 2011 May;33(4):522-39
pubmed: 21545443
Addict Behav. 2021 Feb;113:106679
pubmed: 33032193
PLoS Med. 2021 Mar 11;18(3):e1003564
pubmed: 33705396
J Am Pharm Assoc (2003). 2010 Mar-Apr 1;50(2):140-7
pubmed: 20199954
Indian J Psychiatry. 2015 Jul;57(Suppl 2):S275-85
pubmed: 26330645
Trans Am Clin Climatol Assoc. 2017;128:112-130
pubmed: 28790493
Harm Reduct J. 2021 Jun 10;18(1):62
pubmed: 34112187
Int J Drug Policy. 2015 Dec;26(12):1238-43
pubmed: 26365768
Int J STD AIDS. 2009 Jun;20(6):399-405
pubmed: 19451325
Addiction. 2017 Dec;112(12):2098-2111
pubmed: 28734128
BMC Public Health. 2016 Nov 3;16(1):1136
pubmed: 27809824
Curr Opin HIV AIDS. 2014 Mar;9(2):150-5
pubmed: 24406532
World J Gastroenterol. 2017 Oct 7;23(37):6802-6816
pubmed: 29085224
Int J Drug Policy. 2016 Jan;27:127-31
pubmed: 26764125
Drug Alcohol Depend. 2014 Nov 1;144:259-64
pubmed: 25307745
J Viral Hepat. 2004 Mar;11(2):97-107
pubmed: 14996343
Clin Psychol Rev. 2018 Dec;66:12-23
pubmed: 29174306
Child Youth Serv Rev. 2015 May;52:74-88
pubmed: 25825550
J Drug Issues. 2009;39(3):677-714
pubmed: 20628558
J Infect Dis. 2010 Nov 15;202(10):1500-9
pubmed: 20936979
Drug Alcohol Depend. 2014 Jan 1;134:401-405
pubmed: 24216393
MMWR Recomm Rep. 2012 Nov 9;61(RR-5):1-40
pubmed: 23135062
J Trop Med. 2017;2017:3452513
pubmed: 29181037
J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Jan 1;20(1):67-72
pubmed: 9928732
Int J Drug Policy. 2020 Sep;83:102958
pubmed: 33183679
Harm Reduct J. 2012 Dec 18;9:40
pubmed: 23249619
Psychother Res. 2020 Jul;30(6):718-727
pubmed: 31610768
Infect Dis Rep. 2012 Feb 17;4(1):e19
pubmed: 24470926
Am J Transplant. 2017 Dec;17(12):3241-3252
pubmed: 29145698
J Acquir Immune Defic Syndr Hum Retrovirol. 1996 May 1;12(1):84-92
pubmed: 8624766
J Gastroenterol Hepatol. 2015 Aug;30(8):1237-45
pubmed: 25708186
Clin Microbiol Rev. 2000 Jul;13(3):385-407
pubmed: 10885983
Futures. 2021 Apr;128:102726
pubmed: 34658398
Lancet. 2015 Jan 3;385(9962):55-71
pubmed: 25059947
Harm Reduct J. 2016 Mar 08;13:10
pubmed: 26956029
BMC Public Health. 2020 Jun 5;20(1):867
pubmed: 32503604
Addict Health. 2015 Summer-Autumn;7(3-4):164-73
pubmed: 26885353
BMC Infect Dis. 2020 Oct 9;20(1):742
pubmed: 33036558
Am J Public Health. 2005 Apr;95(4):703-9
pubmed: 15798133
Drug Alcohol Rev. 2012 Sep;31(6):784-9
pubmed: 22449025
Addiction. 2015 Apr;110(4):627-35
pubmed: 25510264
Int J Drug Policy. 2020 Sep;83:102851
pubmed: 32736959
AIDS. 2013 Nov 13;27(17):2665-78
pubmed: 23842129
J Int AIDS Soc. 2020 Jul;23(7):e25583
pubmed: 32697423
J Rural Health. 2018 Dec;34(1):31-41
pubmed: 28685884

Auteurs

Chris Guure (C)

Department of Biostatistics, School of Public Health, University of Ghana, Legon, Accra, Ghana.

Sharren Margaret Obiri-Yeboah Laryea (SM)

Department of Biostatistics, School of Public Health, University of Ghana, Legon, Accra, Ghana.

Samuel Dery (S)

Department of Biostatistics, School of Public Health, University of Ghana, Legon, Accra, Ghana.

Carlota Baptista da Silva (C)

International Consultant, Harm Reduction and Key Population Expert, Lisbon, Portugal.

Comfort Asamoah-Adu (C)

West Africa Program to Combat AIDS, Accra, Ghana.

Stephen Ayisi-Addo (S)

National AIDS/STI Control Programme, Ghana Health Service, Accra, Ghana.

Maria-Goretti Loglo (MG)

International Drug Policy Consortium, East Legon, Accra, Ghana.

Adamu Mohammed (A)

West Africa Behavioural Health Addictions and Recovery Management, Accra, Ghana.

Kwasi Torpey (K)

Department of Population Family and Reproductive Health School of Public Health, University of Ghana, Legon, Accra, Ghana.

Classifications MeSH